Abstract
BACKGROUND: Renal artery stenosis is a common cause of renal ischemia, contributing to the development of chronic kidney disease. To investigate the role of local CD40 expression in renal artery stenosis, Goldblatt 2-kidney 1-clip surgery was per-formed on hypertensive Dahl salt-sensitive rats (S rats) and genetically modified S rats in which CD40 function is abolished (Cd40mutant). METHODS AND RESULTS: Four weeks following the 2-kidney 1-clip procedure, Cd40mutant rats demonstrated significantly reduced blood pressure and renal fibrosis in the ischemic kidneys compared with S rat controls. Similarly, disruption of Cd40 resulted in reduced 24-hour urinary protein excretion in Cd40mutant rats versus S rat controls (46.2±1.9 versus 118.4±5.3 mg/24 h; P<0.01), as well as protection from oxidative stress, as indicated by increased paraoxonase activity in Cd40mutant rats versus S rat controls (P<0.01). Ischemic kidneys from Cd40mutant rats demonstrated a significant decrease in gene expression of the profibrotic mediator, plasminogen activator inhibitor-1 (P<0.05), and the proinflammatory mediators, C-C motif chemokine ligand 19 (P<0.01), C-X-C Motif Chemokine Ligand 9 (P<0.01), and interleukin-6 receptor (P<0.001), compared with S rat ischemic kidneys, as assessed by quantitative PCR assay. Reciprocal renal transplantation docu-mented that CD40 exclusively expressed in the kidney contributes to ischemia-induced renal fibrosis. Furthermore, human CD40-knockout proximal tubule epithelial cells suggested that suppression of CD40 signaling significantly inhibited expression of proinflammatory and-fibrotic genes. CONCLUSIONS: Taken together, our data suggest that activation of CD40 induces a significant proinflammatory and-fibrotic response and represents an attractive therapeutic target for treatment of ischemic renal disease.
| Original language | English |
|---|---|
| Article number | e014072 |
| Journal | Journal of the American Heart Association |
| Volume | 9 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2020 |
Bibliographical note
Publisher Copyright:© 2020 The Authors.
Funding
Dr Kennedy discloses grants from the National Institutes of Health (NIH; HL-137004), American Heart Association (14SDG18650010), David and Helen Boone Foundation Research Fund, Central Society for Clinical and Translational Research, University of Toledo Women and Philanthropy, and Cleveland Clinic Research Program Committee. Dr Tian discloses a US patent (US8981051 B2). Dr Tian discloses grants from the NIH (R01 HL-105649) and the URFO Biomedical Research Innovation Program from the University of Toledo. The remaining authors have no disclosures to report. This work was supported by the National Institutes of Health (HL-137004 and HL-105649), the National Affiliate of the American Heart Association (14SDG18650010 and 16SDG27700030), the American Society of Nephrology (Pre-doctoral Fellowship to Khalaf), the David and Helen Boone Foundation Research Fund, an Early Career Development Award from the Central Society for Clinical and Translational Research, the University of Toledo Women and Philanthropy Genetic Analysis Instrumentation Center, and the University of Toledo Medical Research Society.
| Funders | Funder number |
|---|---|
| Central Society for Clinical and Translational Research | |
| Central Society for Clinical and Translational Research, University of Toledo | R01 HL-105649 |
| Ohio Department of Higher Education, David and Helen Boone Foundation | |
| University of Toledo Medical Research Society | |
| National Institutes of Health (NIH) | HL-105649 |
| National Heart, Lung, and Blood Institute (NHLBI) | R01HL137004 |
| American the American Heart Association | 14SDG18650010, 16SDG27700030 |
| American Society of Nephrology | |
| Department of Mathematics and Statistics, University of Toledo, Toledo, OH |
Keywords
- CD40
- Renal fibrosis
- Renal ischemia
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine